African Rare Diseases Initiative: Advancing Genomic Medicine for rare diseases in Africa
Official title: African Rare Diseases Initiative (ARDI): Advancing Genomic Medicine through rare diseases research in Africa
Funded at Centre de Genetique Humaine · NIH-11358417 · Data updated 2026-11-12
A study aims to map and understand rare diseases in the Democratic Republic of Congo to improve diagnosis, prevention, and care for patients and families.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Centre de Genetique Humaine NIH-funded |
| Lab location | 1 site (Lemba, Congo Dem Rep) |
| Project start | July 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $628,907 |
| NIH project number | 5R01HG012284-04 |
| Project ID | NIH-11358417 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals in the DRC and other Sub-Saharan African regions with suspected or confirmed rare diseases and their families.
✕Less likely to help
Populations outside the target regions or individuals without suspected rare diseases may not directly benefit.
What this research studies
This project focuses on collecting and analyzing genomic data from people in sub-Saharan Africa to understand how rare diseases appear in that population. It emphasizes building regional knowledge, sharing data, and improving digital tools for diagnosis and advocacy. The goal is to create better screening, management plans, and support for patients with rare diseases in Africa, using cloud-based resources and local collaboration. Researchers will work with local clinicians, laboratories, and communities to translate genomic findings into practical benefits for patients.
Why it matters
Potential benefit: If successful, patients in Africa could receive earlier diagnoses, better disease management, and stronger advocacy and resources for rare diseases.
How similar studies have gone: Global efforts show that expanding diverse genomic data improves diagnostic yield for rare diseases, though region-specific data remain limited.
Where this research is happening
-
Centre de Genetique Humaine
Lemba, Congo Dem Rep Active
Researchers
- Principal investigator: Lumaka Zola, Aime — Centre de Genetique Humaine
- Study coordinator: Lumaka Zola, Aime
Related research
Other NIH-funded projects on the same topics.
-
Liver pathobiology from rare liver diseases
A study at UCSF looks at why rare liver conditions cause liver damage, with the aim of finding new ways to diagnose and treat chronic liver disease.
-
Data Management and Coordinating Center support for Rare Diseases Research
A national rare diseases research program is funding a center to manage data and coordinate studies to help improve diagnosis, care, and potential treatments for children with rare conditions.
-
EEG-based drug repurposing for rare CNS diseases
A new approach uses EEG brain signatures to find existing drugs that might help people with rare nervous-system disorders.
-
Ethics of Engaging Patient Groups in Drug Development for Rare Diseases
This grant asks how patient and family groups can ethically help shape rare-disease drug development from idea to market, with input from patients, families, doctors, and researchers.
-
Center for Polyamine Disorders group study of rare metabolic disorders
A research consortium is studying a group of rare metabolic disorders linked to polyamines and aims to understand symptoms, biomarkers, and disease progression to improve care.
-
Encore: speeding up finding new uses for existing drugs to help kids with rare diseases
A big NIH project will test thousands of existing medicines to see if any can help treat rare genetic diseases in children.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.